公开(公告)号：KR1020090022706A

公开(公告)日：2009-03-04

申请号：KR1020070088294

申请日：2007-08-31

Applicant: 한국화학연구원

Inventor： 민용기 ,  유시용 ,  김성환 ,  이수의

IPC: A61K31/19 ,  A61P19/10

Abstract: A pharmaceutical composition including ursolic acid and 2-alpha-hydroxy-ursolic acid is provided to prevent and treat osteoporosis, fracture, periodontal diseases and bone growth disability. A pharmaceutical composition for promoting osteoblast differentiation and activities comprises ursolic acid represented by the formula 1 and 2-alpha-hydroxy-ursolic acid represented by the formula 2 as active ingredients. The ursolic acid and 2-alpha-hydroxy-ursolic acid are extracted from Prunella vulgaris through a column chromatography process. The amount of the ursolic acid and 2-alpha-hydroxy-ursolic acid is 0.0001-50wt% on a total weight basis of the pharmaceutical composition.

Abstract translation: 提供包括熊果酸和2-α-羟基 - 熊果酸的药物组合物，用于预防和治疗骨质疏松症，骨折，牙周病和骨生长障碍。 用于促进成骨细胞分化和活性的药物组合物包括由式1表示的熊果酸和由式2表示的2-α-羟基 - 熊果酸作为活性成分。 熊果酸和2-α-羟基熊果酸通过柱色谱法从普通小提取物中提取。 熊果酸和2-α-羟基 - 熊果酸的量基于药物组合物的总重量为0.0001-50重量％。

公开(公告)号：KR100999458B1

公开(公告)日：2010-12-09

申请号：KR1020080049090

申请日：2008-05-27

Applicant: 한국화학연구원

Inventor： 김성환 ,  민용기 ,  이수의 ,  김영섭 ,  곽한복

IPC: A61K31/7034 ,  A61K31/122 ,  A61P19/10 ,  A61P19/00

CPC classification number: A61K31/7034 ,  A61K31/122

Abstract: 본 발명은 하기 화학식 1의 피지온 글루코피라노사이드(physcion-8-O-β-D-glucopyranoside) 또는 하기 화학식 2의 피지온(physcion)을 포함하는 조골세포의 활성 촉진용 약학 조성물에 관한 것으로서, 본 발명에 따른 약학 조성물은 간엽줄기세포의 조골 세포로의 분화와 조골 세포 분화를 통한 무기질화를 촉진시켜, 골다공증 및 골절 등과 같은 질환 및 증상의 치료 및 예방뿐만 아니라, 골 강화를 목적으로 하는 치주 질환 및 화상으로 비롯되는 골성장 장애의 치료에도 유용하게 사용될 수 있다.




피지온 글루코피라노사이드, 골다공증, 조골 세포, BMP-2, RUNX2, ALP

公开(公告)号：KR1020090123152A

公开(公告)日：2009-12-02

申请号：KR1020080049090

申请日：2008-05-27

Applicant: 한국화학연구원

Inventor： 김성환 ,  민용기 ,  이수의 ,  김영섭 ,  곽한복

IPC: A61K31/7034 ,  A61K31/122 ,  A61P19/10 ,  A61P19/00

CPC classification number: A61K31/7034 ,  A61K31/122

Abstract: PURPOSE: A pharmaceutical composition for promoting osteoblast containing physcion glucopyranoside or physcion is provided to promote mineralize mesenchymal stem cell and prevent and treat disease and symptom such as osteoporosis and fracture. CONSTITUTION: A pharmaceutical composition for preventing or treating bone disease contains 0.0001~50 weight% of physcion-8-O-β-D-glucopyranoside of chemical formula 1 or physcion of chemical formula 2 as an active ingredient. Bone disease includes fracture, osteoporosis, periodontal disease and bone growth failure. The physcion-8-O-β-D-glucopyranoside is administered in 1~150mg/kg per day. The physcion-8-O-β-D-glucopyranoside or physcion is isolated from Polygonum multiflorum.

Abstract translation: 目的：提供一种用于促进成骨细胞含有生物学药物的药物组合物，用于促进矿化间充质干细胞，预防和治疗骨质疏松症和骨折等疾病和症状。 构成：用于预防或治疗骨病的药物组合物含有化学式1的化学式8-O-β-D-吡喃葡萄糖苷或化学式2的化学式为0.0001-50重量％的活性成分。 骨病包括骨折，骨质疏松症，牙周病和骨生长失败。 生物-​​8-O-β-D-吡喃葡萄糖苷每天以1〜150mg / kg施用。 生物-​​8-O-β-D-吡喃葡萄糖苷或from ion从Poly is中分离出来。

公开(公告)号：KR1020090058716A

公开(公告)日：2009-06-10

申请号：KR1020070125443

申请日：2007-12-05

Applicant: 한국화학연구원

Inventor： 민용기 ,  김영섭 ,  김성환 ,  이수의 ,  김명희

IPC: A61K31/352 ,  A61P19/10 ,  A61P1/02

Abstract: A pharmaceutical composition for preventing and treating bone disease is provided to decrease bone resorption and enhance bone formation by using a baicalein. A pharmaceutical composition for preventing and treating bone disease comprises a baicalein of the chemical formula 1 as an active ingredient. The bone disease is selected from osteoporosis, fracture, periodontal disease and bone growth failure. The baicalein is contained in the amount of 0.0001-50 weight% based on total weight. The composition further comprises a pharmaceutically allowable additive.

Abstract translation: 提供了用于预防和治疗骨病的药物组合物，以通过使用黄芩素来减少骨吸收并增强骨形成。 用于预防和治疗骨疾病的药物组合物包含化学式1的黄芩素作为活性成分。 骨疾病选自骨质疏松症，骨折，牙周病和骨生长失败。 黄芩素的含量占总重量的0.0001-50重量％。 组合物还包含药学上可允许的添加剂。